1-(3-氨基丙基)哌啶-4-羧酰胺 | 4608-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(3-氨基丙基)哌啶-4-羧酰胺
• 中文别名: 1-(3-氨基丙基)-4-哌啶甲酰胺
• 英文名称: 1-(3-Aminopropyl)piperidine-4-carboxamide
• CAS: 4608-79-1
• 化学式: C₉H₁₉N₃O
• mdl: MFCD08686836
• 分子量: 185.27
• InChiKey: SZYRASLRZWJIEC-UHFFFAOYSA-N

物化性质

• 熔点：
  85-88 °C
• 沸点：
  375.1±42.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090

文献信息

• Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes
  申请人：Heraeus Precious Metals North America Conshohocken LLC

  公开号：US11289238B2

  公开（公告）日：2022-03-29

  A solvent-free electroconductive composition may be used to make electroconductive lines on a surface of a substrate or electroconductive plugs within via holes of a substrate. The solvent-free electroconductive composition is generally made of about 40 to about 95 wt % of a conductive component, about 4 to about 30 wt % of a polymer or oligomer comprising a reactive functional group, up to about 20 wt % of a monomeric diluent comprising a reactive functional group, and up to about 3 wt % of a curing agent. In some instances, the solvent-free electroconductive composition further includes up to about 3 wt % of a lubricating compound. Substrates made using solvent-free electroconductive compositions may be used in printed circuit boards, integrated circuits, solar cells, capacitors, resistors, thermistors, varistors, resonators, transducers, inductors, and multilayer ferrite beads.

  无溶剂导电组合物可用于在基材表面制作导电线或在基材通孔内制作导电塞。无溶剂导电组合物一般由约 40 至约 95 wt % 的导电成分、约 4 至约 30 wt % 含有活性官能团的聚合物或低聚物、最多约 20 wt % 含有活性官能团的单体稀释剂和最多约 3 wt % 的固化剂组成。在某些情况下，无溶剂导电组合物还包括最多约 3 wt % 的润滑化合物。使用无溶剂导电组合物制成的基板可用于印刷电路板、集成电路、太阳能电池、电容器、电阻器、热敏电阻器、压敏电阻器、谐振器、传感器、电感器和多层铁氧体磁珠。
• MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS
  申请人：Biohaven Therapeutics Ltd.

  公开号：EP4017492A1

  公开（公告）日：2022-06-29
• COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES
  申请人：Heraeus Precious Metals North America Conshohocken LLC.

  公开号：US20210174983A1

  公开（公告）日：2021-06-10

  A solvent-free electroconductive composition may be used to make electroconductive lines on a surface of a substrate or electroconductive plugs within via holes of a substrate. The solvent-free electroconductive composition is generally made of about 40 to about 95 wt % of a conductive component, about 4 to about 30 wt % of a polymer or oligomer comprising a reactive functional group, up to about 20 wt % of a monomeric diluent comprising a reactive functional group, and up to about 3 wt % of a curing agent. In some instances, the solvent-free electroconductive composition further includes up to about 3 wt % of a lubricating compound. Substrates made using solvent-free electroconductive compositions may be used in printed circuit boards, integrated circuits, solar cells, capacitors, resistors, thermistors, varistors, resonators, transducers, inductors, and multilayer ferrite beads.
• [EN] 1-(3-AMINO-PROPYL)-PIPERIDIN-4-YL-AMIDES, PHARMACEUTICAL COMPOSITIONS, PROCESSES FOR THEIR PREPARATION AND USES<br/>[FR] 1-(3-AMINO-PROPYL)-PIPÉRIDIN-4-YL-AMIDES, COMPOSITIONS PHARMACEUTIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET UTILISATIONS
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2009052708A1

  公开（公告）日：2009-04-30

  1-(3-Amino-propyl)-piperidin-4-yl-amides as the following formula, pharmaceutically acceptable salts thereof , compositions thereof, and processes for preparing them. These compounds or their pharmaceutically acceptable salts could be used as antagonists of CCR5, are used to prepare drugs for treatment of CCR5 mediated diseases or HIV infection, asthma, rheumatoidarthritis, autoimmune diseases, chronic obstructive pulmonary disease(COPD).
• [EN] MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS<br/>[FR] MOLÉCULES QUI SE LIENT À TDP-43 POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE ET DE TROUBLES APPARENTÉS
  申请人：BIOHAVEN THERAPEUTICS LTD

  公开号：WO2021035101A1

  公开（公告）日：2021-02-25

  Pharmaceutical compositions of the invention comprise TDP-43 binding agents having a disease-modifying action in the treatment of diseases associated with TDP-43 that include ALS, FTLD, CTE, hippocampal sclerosis of aging (CARTS), Alzheimers disease, and Alzheimers disease related disorder, and disease that involve excess amounts of TDP-43 in the cytosol.